These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22180675)

  • 1. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.
    Dimberu PM; Leonhardt RM
    Yale J Biol Med; 2011 Dec; 84(4):371-80. PubMed ID: 22180675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting human herpesvirus immune evasion for therapeutic gain: potential and pitfalls.
    Horst D; Ressing ME; Wiertz EJ
    Immunol Cell Biol; 2011 Mar; 89(3):359-66. PubMed ID: 21301483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
    de Charette M; Marabelle A; Houot R
    Eur J Cancer; 2016 Nov; 68():134-147. PubMed ID: 27755997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The urgent need to recover MHC class I in cancers for effective immunotherapy.
    Garrido F; Aptsiauri N; Doorduijn EM; Garcia Lora AM; van Hall T
    Curr Opin Immunol; 2016 Apr; 39():44-51. PubMed ID: 26796069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosurveillance and immunoediting--can the immune response be made more "immunodemocratic"?
    Mincheff M
    J BUON; 2009 Sep; 14 Suppl 1():S89-96. PubMed ID: 19785075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.
    Ma W; Smith T; Bogin V; Zhang Y; Ozkan C; Ozkan M; Hayden M; Schroter S; Carrier E; Messmer D; Kumar V; Minev B
    J Transl Med; 2011 Mar; 9():34. PubMed ID: 21450109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour surveillance: missing peptides and MHC molecules.
    Khanna R
    Immunol Cell Biol; 1998 Feb; 76(1):20-6. PubMed ID: 9553772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
    Seliger B
    HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to counteract MHC-I defects in tumors.
    Lampen MH; van Hall T
    Curr Opin Immunol; 2011 Apr; 23(2):293-8. PubMed ID: 21295956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the power of the immune system in cancer immunotherapy and cancer prevention.
    Lu YC; Wang XJ
    Mol Carcinog; 2020 Jul; 59(7):675-678. PubMed ID: 32386070
    [No Abstract]   [Full Text] [Related]  

  • 12. Aspects of cancer immunotherapy.
    McKenzie IF; Apostolopoulos V; Plebanski M; Pietersz GA; Loveland BE
    Immunol Cell Biol; 2003 Feb; 81(1):79-85. PubMed ID: 12534951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer and the Immune System: Basic Concepts and Targets for Intervention.
    Pardoll D
    Semin Oncol; 2015 Aug; 42(4):523-38. PubMed ID: 26320058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of novel immunotherapy targeting cancer immune evasion].
    Tamada K
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies for cancer immunotherapy.
    Weiner LM; Dhodapkar MV; Ferrone S
    Lancet; 2009 Mar; 373(9668):1033-40. PubMed ID: 19304016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell biology and its role in tumor immunotherapy.
    Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
    J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunoinformatics of cancer immunotherapy.
    Deluca DS; Blasczyk R
    Tissue Antigens; 2007 Oct; 70(4):265-71. PubMed ID: 17767547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy and immunomonitoring (CITIM): redefining cancer therapy.
    Malyguine A; Umansky V; Shurin MR
    J Immunotoxicol; 2009 Dec; 6(4):205-8. PubMed ID: 19908938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.